Twenty-year trends in benzodiazepine dispensing in the Australian population

Internal Medicine Journal

Volumn 44, Issue 1, 2014, Pages 57-64

  Islam, M M ^a   Conigrave, K M ^b,c,d   Day, C A ^c   Nguyen, Y ^c   Haber, P S ^c,e  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e SYDNEY LOCAL HEALTH DISTRICT   (Australia)

Author keywords

Anxiolytic drug; Ashton equivalent dose; Benzodiazepine; Defined daily dose; Hypnotic; Sedative

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CHLORDIAZEPOXIDE; CLOBAZAM; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; FLUNITRAZEPAM; FLURAZEPAM; LORAZEPAM; MIDAZOLAM; NITRAZEPAM; OXAZEPAM; TEMAZEPAM; TRIAZOLAM; ZOLPIDEM; ZOPICLONE;

ARTICLE; AUSTRALIA; DEFINED DAILY DOSE; DRUG DOSE REGIMEN; DRUG UTILIZATION; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; TABLET; TREND STUDY; WORLD HEALTH ORGANIZATION;

ANXIOLYTIC DRUG; ASHTON EQUIVALENT DOSE; BENZODIAZEPINE; DEFINED DAILY DOSE; HYPNOTIC; SEDATIVE;

AUSTRALIA; BENZODIAZEPINES; DRUG PRESCRIPTIONS; DRUG UTILIZATION; HUMANS; INAPPROPRIATE PRESCRIBING; INSURANCE, PHARMACEUTICAL SERVICES; RETROSPECTIVE STUDIES; THERAPEUTIC EQUIVALENCY;

EID: 84892868499     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12315     Document Type: Article

References (26)

1. Cloos J-M, Ferreira VR. Current use of benzodiazepines in anxiety disorders. Curr Opin Psychiatry 2008; 22: 90-95.
2. Sim MG, Khong E, Wain TD. The prescribing dilemma of benzodiazepines. Aust Fam Physician 2007; 36: 923-926.
3. Spinks A, Bulbeck K, Mar CD, Glaziou P, Nikles J. Using Benzodiazepines: The Best Evidence. Brisbane: Centre for General Practice, University of Queensland; 2000; 77.
4. Ashton H. Benzodiazepine dependence. In: Haddad P, Dursun S, Deakin B, eds. Adverse Syndromes and Psychiatric Drugs. Oxford: Oxford University Press; 2004; 239-260.
5. Voshaar RC, Couvee JE, van Balkom AJ, Mulder PG, Zitman FG. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry 2006; 189: 213-220.
6. Gray SL, LaCroix AZ, Hanlon JT, Penninx BW, Blough DK, Leveille SG etal. Benzodiazepine use and physical disability in community-dwelling older adults. J Am Geriatr Soc 2006; 54: 224-230.
7. Pariente A, Dartigues JF, Benichou J, Letenneur L, Moore N, Fourrier-Reglat A. Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging 2008; 25: 61-70.
8. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004; 18: 37-48.
9. Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs 2009; 23: 19-34.
10. Mant A, Whicker SD, McManus P, Birkett DJ, Edmonds D, Dumbrell D. Benzodiazepine utilisation in Australia: report from a new pharmacoepidemiological database. Aust J Public Health 1993; 17: 345-349.
11. Britt H, Miller GC, Charles J, Pan Y, Valenti L, Henderson J etal. General practice activity in Australia 2005-06. General Practice Vol. cat. No GEP 19. Canberra: Australian Institute of Health and Welfare 2007.
12. Hollingworth SA, Siskind DJ. Anxiolytic, hypnotic and sedative medication use in Australia. Pharmacoepidemiol Drug Saf 2010; 19: 280-288.
13. Smith AJ, Sketris I, Cooke C, Gardner D, Kisely S, Tett SE. A comparison of benzodiazepine and related drug use in Nova Scotia and Australia. Can J Psychiatry. 2008; 53: 545-552.
14. Ashton CH. Chapter I: the benzodiazepines: what they do in the body (The Ashton Manual). Benzodiazepines: how they work and how to withdraw. 2002 [cited 2013 May]. Available from URL: http://www.benzo.org.uk/manual/bzcha01.htm
15. Stephenson CP, Karanges E, McGregor IS. Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. Aust N Z J Psychiatry 2013; 47: 74-87.
16. World Health Organization. Guidelines for ATC Classification and DDD Assignment. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2012.
17. Therapeutic Goods Administration. Medicine regulator places boxed warning on Stilnox. 2008. [cited 2012 Dec 22]. Available from URL: http://www.tga.gov.au/newsroom/media-2008-stilnox-080221.htm
18. Smith AJ, Tett SE. How do different age groups use benzodiazepines and antidepressants? Analysis of an Australian administrative database, 2003-6. Drugs Aging 2009; 26: 113-122.
19. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Depression. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry 2004; 38: 389-407.
20. Theodorou AA, Johnson KM, Slezak J, Szychowski JA. Recent trends in utilization of antianxiety medication. Am J Pharm Benefits 2009; 1: 225-229.
21. Rintoul AC, Dobbin MD, Nielsen S, Degenhardt L, Drummer OH. Recent increase in detection of alprazolam in Victorian heroin-related deaths. Med J Aust 2013; 198: 206-209.
22. Moylan S, Giorlando F, Nordfjaern T, Berk M. The role of alprazolam for the treatment of panic disorder in Australia. Aust N Z J Psychiatry 2012; 46: 212-224.
23. Monheit B. Prescription drug misuse. Aust Fam Physician 2010; 39: 540-546.
24. Conigrave K. Alprazolam linked to heroin deaths. Med J Aust InSight. 2013; March.
25. Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf. 2003; 26: 261-282.
26. Weintraub M, Singh S, Byrne L, Maharaj K, Guttmacher L. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA 1991; 266: 2392-2397.